| pubmed-article:15555877 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15555877 | lifeskim:mentions | umls-concept:C0314760 | lld:lifeskim |
| pubmed-article:15555877 | lifeskim:mentions | umls-concept:C0021853 | lld:lifeskim |
| pubmed-article:15555877 | lifeskim:mentions | umls-concept:C0597979 | lld:lifeskim |
| pubmed-article:15555877 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:15555877 | lifeskim:mentions | umls-concept:C0683598 | lld:lifeskim |
| pubmed-article:15555877 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:15555877 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:15555877 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:15555877 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:15555877 | pubmed:dateCreated | 2004-11-23 | lld:pubmed |
| pubmed-article:15555877 | pubmed:abstractText | The aim of the present study was to determine whether oral targeted recombinant beta-lactamase (TRBL) administration could overcome the development of ampicillin-induced resistance in the gut microbiota. Eighteen laboratory beagles with permanent jejunal fistula were randomised to receive ampicillin + placebo, ampicillin + TRBL or placebo. A total of 982 coliform isolates, collected from jejunal and faecal samples before, during and after the treatment were tested against nine antimicrobials. The proportion of ampicillin resistance (multi-resistance) among coliform isolates increased from 20 to 36% in the ampicillin + placebo group but far less, 20-36%, in the ampicillin + TRBL group. These results indicate that TRBL may prevent the emergence of beta-lactam-associated resistance in coliforms in the gut. | lld:pubmed |
| pubmed-article:15555877 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15555877 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15555877 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15555877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15555877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15555877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15555877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15555877 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15555877 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:15555877 | pubmed:issn | 0924-8579 | lld:pubmed |
| pubmed-article:15555877 | pubmed:author | pubmed-author:HuovinenPentt... | lld:pubmed |
| pubmed-article:15555877 | pubmed:author | pubmed-author:WestermarckEl... | lld:pubmed |
| pubmed-article:15555877 | pubmed:author | pubmed-author:HarmoinenJaan... | lld:pubmed |
| pubmed-article:15555877 | pubmed:author | pubmed-author:MentulaSiljaS | lld:pubmed |
| pubmed-article:15555877 | pubmed:author | pubmed-author:KönönenEijaE | lld:pubmed |
| pubmed-article:15555877 | pubmed:author | pubmed-author:KoskiPerttiP | lld:pubmed |
| pubmed-article:15555877 | pubmed:author | pubmed-author:RautioMerjaM | lld:pubmed |
| pubmed-article:15555877 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15555877 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:15555877 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15555877 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15555877 | pubmed:pagination | 555-61 | lld:pubmed |
| pubmed-article:15555877 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15555877 | pubmed:meshHeading | pubmed-meshheading:15555877... | lld:pubmed |
| pubmed-article:15555877 | pubmed:meshHeading | pubmed-meshheading:15555877... | lld:pubmed |
| pubmed-article:15555877 | pubmed:meshHeading | pubmed-meshheading:15555877... | lld:pubmed |
| pubmed-article:15555877 | pubmed:meshHeading | pubmed-meshheading:15555877... | lld:pubmed |
| pubmed-article:15555877 | pubmed:meshHeading | pubmed-meshheading:15555877... | lld:pubmed |
| pubmed-article:15555877 | pubmed:meshHeading | pubmed-meshheading:15555877... | lld:pubmed |
| pubmed-article:15555877 | pubmed:meshHeading | pubmed-meshheading:15555877... | lld:pubmed |
| pubmed-article:15555877 | pubmed:meshHeading | pubmed-meshheading:15555877... | lld:pubmed |
| pubmed-article:15555877 | pubmed:meshHeading | pubmed-meshheading:15555877... | lld:pubmed |
| pubmed-article:15555877 | pubmed:meshHeading | pubmed-meshheading:15555877... | lld:pubmed |
| pubmed-article:15555877 | pubmed:meshHeading | pubmed-meshheading:15555877... | lld:pubmed |
| pubmed-article:15555877 | pubmed:meshHeading | pubmed-meshheading:15555877... | lld:pubmed |
| pubmed-article:15555877 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15555877 | pubmed:articleTitle | Inhibition of ampicillin-induced emergence of resistance in intestinal coliforms by targeted recombinant beta-lactamase. | lld:pubmed |
| pubmed-article:15555877 | pubmed:affiliation | Anaerobe Reference Laboratory, Department of Microbiology, National Public Health Institute (KTL), Mannerheimintie 166, FIN-00300 Helsinki, Finland. silja.mentula@ktl.fi | lld:pubmed |
| pubmed-article:15555877 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15555877 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
